Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

被引：13
作者：
Paiva, Bruno [6 ]
Zherniakova, Anastasiia
Nunez-Cordoba, Jorge M.
Rodriguez-Otero, Paula
Shi, Qian [1 ]
Munshi, Nikhil C. [2 ]
Durie, Brian G. M. [3 ,4 ,5 ]
San-Miguel, Jesus
机构：
[1] Univ Navarra, Canc Ctr Clin, Sinai Med Ctr CB16, Ctr Invest Med Aplicada,Inst Invest Sanitaria Nava, Pamplona 00369, Spain
[2] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA
[3] Dana Farber Canc Inst, Boston, MA USA
[4] Boston VA Healthcare Syst, Boston, MA USA
[5] Cedars Sinai Med Ctr, Los Angeles, CA USA
[6] Clin Univ Navarra, Ctr Invest Med Aplicada, Ctr Invest Biomed Red Canc, Inst Invest Sanitaria Navarra, Pamplona 31008, Spain
来源：
BLOOD ADVANCES | 2024年 / 8卷 / 01期
关键词：
OPEN-LABEL; DEXAMETHASONE; BORTEZOMIB; LENALIDOMIDE; CARFILZOMIB; DARATUMUMAB; SURVIVAL; TRANSPLANTATION; MULTICENTER; OUTCOMES;
D O I：
10.1182/bloodadvances.2023010821
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：219 / 223
页数：5
相关论文
共 22 条
  • [1] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
    Attal, Michel
    Richardson, Paul G.
    Rajkumar, S. Vincent
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Mace, Sandrine
    Corzo, Kathryn P.
    Campana, Frank
    Le-Guennec, Solenn
    Dubin, Franck
    Anderson, Kenneth C.
    [J]. LANCET, 2019, 394 (10214) : 2096 - 2107
  • [2] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
    Attal, Michel
    Lauwers-Cances, Valerie
    Hulin, Cyrille
    Leleu, Xavier
    Caillot, Denis
    Escoffre, Martine
    Arnulf, Bertrand
    Macro, Margaret
    Belhadj, Karim
    Garderet, Laurent
    Roussel, Murielle
    Payen, Catherine
    Mathiot, Claire
    Fermand, Jean P.
    Meuleman, Nathalie
    Rollet, Sandrine
    Maglio, Michelle E.
    Zeytoonjian, Andrea A.
    Weller, Edie A.
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    Facon, Thierry
    Avet-Loiseau, Herve
    Harousseau, Jean-Luc
    Moreau, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) : 1311 - 1320
  • [3] Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
    Avet-Loiseau, Herve
    Ludwig, Heinz
    Landgren, Ola
    Paiva, Bruno
    Morris, Chris
    Yang, Hui
    Zhou, Kefei
    Ro, Sunhee
    Mateos, Maria-Victoria
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01) : E30 - E37
  • [4] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
    Bahlis, Nizar J.
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Krevvata, Maria
    Chiu, Christopher
    Qin, Xiang
    Okonkwo, Linda
    Trivedi, Sonali
    Ukropec, Jon
    Qi, Ming
    San-Miguel, Jesus
    [J]. LEUKEMIA, 2020, 34 (07) : 1875 - 1884
  • [5] Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence
    Ciani, Oriana
    Grigore, Bogdan
    Taylor, Rod S.
    [J]. HEALTH ECONOMICS, 2022, 31 : 44 - 72
  • [6] Dimopoulos MA, 2021, LANCET ONCOL, V22, P801, DOI 10.1016/S1470-2045(21)00128-5
  • [7] Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
    Dytfeld, Dominik
    Wrobel, Tomasz
    Jamroziak, Krzysztof
    Kubicki, Tadeusz
    Robak, Pawel
    Walter-Croneck, Adam
    Czyz, Jaroslaw
    Tyczynska, Agata
    Druzd-Sitek, Agnieszka
    Giannopoulos, Krzysztof
    Nowicki, Adam
    Szczepaniak, Tomasz
    Lojko-Dankowska, Anna
    Matuszak, Magdalena
    Gil, Lidia
    Pula, Bartosz
    Rybka, Justyna
    Majcherek, Maciej
    Usnarska-Zubkiewicz, Lidia
    Szukalski, Lukasz
    Konska, Agnieszka
    Zaucha, Jan Maciej
    Walewski, Jan
    Mikulski, Damian
    Czabak, Olga
    Robak, Tadeusz
    Lahoud, Oscar B.
    Zonder, Jeffrey A.
    Griffith, Kent
    Stefka, Andrew
    Major, Ajay
    Derman, Benjamin A.
    Jakubowiak, Andrzej J.
    [J]. LANCET ONCOLOGY, 2023, 24 (02) : 139 - 150
  • [8] Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
    Facon, Thierry
    Kumar, Shaji K.
    Plesner, Torben
    Orlowski, Robert Z.
    Moreau, Philippe
    Bahlis, Nizar
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Mace, Joseph R.
    Raje, Noopur
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Ahmadi, Tahamtan
    Wang, Jianping
    Van Rampelbergh, Rian
    Uhlar, Clarissa M.
    Tromp, Brenda
    Delioukina, Maria
    Vermeulen, Jessica
    Usmani, Saad Z.
    [J]. LANCET ONCOLOGY, 2021, 22 (11) : 1582 - 1596
  • [9] Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Lee, Jae Hoon
    Moreau, Philippe
    Niesvizky, Ruben
    Dimopoulos, Meletios
    Hajek, Roman
    Pour, Ludek
    Jurczyszyn, Artur
    Qiu, Lugui
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Osman, Muhtarjan
    Paiva, Bruno
    San-Miguel, Jesus
    [J]. BLOOD, 2019, 133 (18) : 1953 - 1963
  • [10] Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis
    Ficek, Joseph
    Kalaitzaki, Eleftheria
    Yuan, Shuai Sammy
    Tosolini, Alessandra
    Du, Ling
    Kremer, Brandon E.
    Davy, Katherine
    Zhou, Helen
    Chen, Tai-Tsang
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (05) : E213 - E221
123